文献速递帕金森病与运动障碍

α-突触核蛋白种子扩增试验扩增参数与前驱期帕金森病进展风险

α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease.
PubMed 文献 · Neurology · 2025-02-06

研究分析帕金森病进展标志物计划中1,027名参与者的脑脊液αSyn-SAA结果,发现前驱期帕金森病和帕金森病患者中αSyn-SAA阳性者扩增更快、曲线下面积更高,且前驱期帕金森病患者中αSyn-SAA阳性且达阈时间更快者表型转化率更高。

要点

  • 前驱期帕金森病和帕金森病患者αSyn-SAA阳性者扩增参数较非 manifesting 携带者和健康对照更快更高。
  • 前驱期帕金森病患者中αSyn-SAA阳性且达阈时间更快者表型转化率更高。
  • 48名前驱期帕金森病患者的纵向检测结果无变化。

核心结论

  • αSyn-SAA阳性和更快的种子扩增与高危个体发生帕金森病的风险更高相关,可能有助于预测表型转化。

研究设计与样本

  • 横断面和纵向分析帕金森病进展标志物计划参与者的脑脊液αSyn-SAA结果,共1,027名参与者(159名健康对照、247名非 manifesting 携带者、96名前驱期帕金森病患者、525名帕金森病患者)。

主要发现

  • 前驱期帕金森病和帕金森病患者中αSyn-SAA阳性者的达阈时间和达50%最大荧光时间更快,曲线下面积更高,与非 manifesting 携带者和健康对照相比(Kruskal-Wallis χ2=4.15-13.96,p<0.0002-0.04)。
  • 前驱期帕金森病患者中αSyn-SAA阳性且达阈时间更快者表型转化率更高(log-rank p=0.001,趋势检验log-rank p<0.0001)。
  • 48名前驱期帕金森病患者的纵向检测结果无变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Tools are needed to evaluate the risk of developing Parkinson disease (PD) in at-risk populations. In this study, we examine differences in alpha-synuclein seed amplification assay (αSyn-SAA) qualitative results and amplification parameters between nonmanifesting carriers (NMCs) of PD-related pathogenic variants, prodromal PD, and PD and the risk of developing a synucleinopathy in participants with prodromal PD. METHODS: Cross-sectional and longitudinal CSF αSyn-SAA results from participants in the Parkinson's Progression Markers Initiative were analyzed. αSyn-SAA positivity and amplification parameters (maximum fluorescence [Fmax], time-to-threshold [TTT], time-to-50% Fmax [T50], and area under the curve [AUC]) were compared between NMCs, participants with prodromal PD, and participants with PD, and their relationship with the likelihood of phenoconversion in participants with prodromal PD was investigated. RESULTS: Samples from 1,027 participants were analyzed (159 healthy controls [HCs], 247 NMCs, 96 participants with prodromal PD, and 525 participants with PD). TTT and T50 were faster, and AUC was higher in αSyn-SAA+ participants with prodromal PD and PD than αSyn-SAA+ NMCs and HC participants (Kruskal-Wallis χ2 = 4.15-13.96, p < 0.0002-0.04). Participants with prodromal PD with positive αSyn-SAA tests and faster TTT had higher rates of phenoconversion (log-rank p = 0.001 and log-rank test-for-trend p < 0.0001). There were no changes in 48 participants with prodromal PD with longitudinal assays. DISCUSSION: αSyn-SAA positivity and faster seed amplification are associated with a greater risk of developing PD in at-risk individuals and may aid in predicting phenoconversion.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Coughlin DG, Shifflett B, Farris CM, et al. α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease. Neurology. 2025. PMID: 39913882. doi:10.1212/WNL.0000000000210279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。